Actelion Ltd is a Swiss biopharmaceutical company with a global presence that focuses on the discovery, development and commercialization of treatments to serve unmet medical needs. Its products specialize in conditions related to the endothelium, the single layer of cells separating every blood vessel from the blood stream. The Company has three approved drugs on the market. Tracleer, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension, a chronic, life-threatening disorder that severely compromises the functions of the lungs and heart. The second product, Zavesca, was in-licensed from Oxford GlycoSciences. Zavesca is an approved oral treatment for type 1 Gaucher disease, a rare debilitating metabolic disorder. Ventavis, the third product, is an inhaled synthetic analogue of prostacyclin that produces potent pulmonary vasodilation and inhibits platelet aggregation, among other benefits.

Genetic Technologies Limited operates as a life science company, specializing in the fields of genetics and genomics primarily in Australia. The company provides genetic testing services to human beings for disease susceptibility, parentage, individual identity, forensics, and sports performance; animals, such as dogs, horses, birds, alpacas, exotics, and zoo animals for parentage, pedigree, traits, and disease susceptibility; and plants for traits and disease susceptibility. It also offers canine reproductive services, as well as involves in licensing its non-coding DNA patents. The company was formerly known as Duketon Goldfields N.L. and changed its name to Genetic Technologies Limited in August 2000. Genetic Technologies Limited was incorporated in 1987 and is based in Fitzroy, Australia.

Actavis U.S. is the US manufacturing and marketing unit of global generics firm Actavis. The company makes a wide variety of generic equivalents of both prescription and OTC drugs, in a number of forms, including liquids, tablets, creams, and suppositories. Among other consumer and specialty drugs, it makes acetaminophen, ibuprofen, and generic Rogaine. It has also launched generic versions of Pfizer's diabetes drug Glucotrol XL and GlaxoSmithKlein's Coreg tables for hypertension and myocardial infarction. Actavis U.S. has manufacturing facilities in Maryland, New Jersey, and North Carolina, from which it ships its own products and provides contract manufacturing services to third parties.

EpiCept has made leukemia remission its entire mission. Its lead cancer drug candidate, Ceplene, is designed for use in adult patients who have had a complete remission from acute myeloid leukemia, but who are still at risk for relapse. It has been approved for use, along with interleukin-2, as a remission maintenance therapy in the EU, and it is awaiting approval in the US. The company's pipeline includes other cancer candidates, as well as topical analgesics for both acute and chronic pain. However, EpiCept has put all drug-discovery work on the back burner to focus on bringing Ceplene to market.

Prolexys Pharmaceuticals wouldn't necessarily characterize proteins as difficult to characterize, especially not if it's using the technology it developed. The biotech research firm's HySpec and HyNet are high-throughput systems for protein expression, purification, and analysis. Prolexys, formerly known as Myriad Proteomics, has also developed its own bioinformatics to put together protein interaction maps from the data generated by HySpec and HyNet. The company has been focusing on cancer research, working with groups such as Columbia University and the Tower Cancer Research Foundation to study advanced solid tumors. Myriad Genetics spun off Prolexys, which was founded in 2001, as a private company in 2003.

IBEX Technologies Inc. company develops and sells a series of proprietary enzymes for use in pharmaceutical research, particularly for arthritis and oncology. It markets diagnostic assays for use in arthritis tests that monitor the deterioration of cartilage; other assays monitor the rebuilding of cartilage. IBEX also provides enzymes for use as reagents used in hemostasis monitoring devices (for blood coagulation detection during certain surgical procedures). The majority of the company's sales are in the US (50%), followed by Europe and Canada, where sales revenues are split evenly. The publicly-traded company, founded in 1972, is led by CEO Paul Baehr.

Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel. Pluristem Therapeutics Inc., a development stage bio-therapeutics company, engages in the research, development, and production of placental-derived adherent stromal cells (ASCs). The company also involves in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of various severe degenerative, ischemic, and autoimmune disorders. It develops a pipeline of products that are derived from the human placenta, a non-controversial, non-embryonic, and adult stem cell source. These placental adherent stromal cells (ASCs) are expanded in the company’s proprietary PluriX three-dimensional bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. The company’s principal product under Phase I clinical trial is PLX-PAD for people suffering from peripheral artery disease. Its pre-clinical products include PLX-IBD for inflammatory bowel diseases; PLX-STROKE for ischemic strokes; PLX-BMT for bone marrow transplantation; and PLX-MS for multiple sclerosis. The company was formerly known as Pluristem Life Systems Inc. and changed its name to Pluristem Therapeutics Inc. in November 2007.

Fertile minds at Merck Serono help people around the world combat infertility. One of the world's top biotechs, Merck Serono focuses on recombinant genetic engineering to develop drugs. The firm also manufactures and markets therapies for neurological, dermatological, metabolic, oncology, cardiovascular, and growth disorders. It is a leader in reproductive health, with flagship drug Gonal-F at the head of its infertility product line. Other key products include beta interferon drug Rebif for the treatment of multiple sclerosis (MS) and colorectal and head/neck cancer treatment Erbitux. The company is a subsidiary of German drugmaker Merck KGaA.

Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California. Aeolus Pharmaceuticals, Inc. (Aeolus) is a pharmaceutical company engaged in development of medical countermeasures against biological, chemical and radiological weapons, as well as for diseases and disorders of the central nervous system, respiratory system, autoimmune system and oncology. The Company is testing its lead compound, AEOL 10150, in a range of indications each in various stages of development. The Company’s lead indications are a medical countermeasure against the effects of acute radiation syndrome (ARS) in the lungs and in the gastro-intestinal tract, and a medical countermeasure against the effects of sulfur mustard gas and chlorine gas. The Company is also developing its second drug candidate AEOL 11207 for the treatment of epilepsy and Parkinson’s disease.

MDRNA, Inc. company was founded in 1983 and is headquartered in Bothell, Washington. MDRNA, Inc. operates as a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The company seeks to improve human health by combining RNAi-based compounds and proprietary peptide- and liposomal-based drug delivery technologies to provide therapeutic options. MDRNA's multi-disciplinary portfolio of capabilities includes molecular biology, cellular biology, formulation expertise, peptide and alkylated amino acid chemistry, pharmacology, toxicology, and bioinformatics. The company is applying this expertise to a single, integrated drug discovery platform that would be the engine for its clinical pipeline and a versatile platform for establishing therapeutic partnerships. MDRNA is also building on new technologies, such as UsiRNAs that incorporate the non-nucleotide moiety Unlocked Nucleobase Analog (UNA) within the siRNA molecule, that might lead to safer and more effective RNAi-based therapeutics. The company combines expertise in siRNA science with proven delivery platforms and a growing IP portfolio, positioning MDRNA as an RNAi therapeutics company and a value-added collaborator for its research partners.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.